Xianqi Feng

Dr. Xianqi Feng

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2022 in Clinical Case Reports
Verified
Journal Article
Open access
MWMengying Wang
Mengying Wang
RMRuoyu Meng
Ruoyu Meng
YGYan Gao
Yan Gao
JHJunxia Huang
Junxia Huang
TLTianlan Li
Tianlan Li
XFXianqi Feng
Xianqi Feng
To explore the clinical characteristics, diagnosis, and treatment of chronic lymphocytic leukemia with secondary pancytopenia. Here, a case of pancytopenia secondary to chronic lymphocytic leukemia is reported. Additionally, a review of relevant chronic lymphocytic leukemia literature was conducted to summarize its diagnosis, clinical characteristics, treatment history, and experience. After treatment with cyclosporine A, the patient's chronic lymphocytic leukemia continued to resolve, and hematopoiesis returned to normal. Cyclosporine A therapy resulted in improved patient outcomes. However, the mechanism by which cyclosporine A rebuilds the immune microenvironment and its antileukemia effect in the body remains to be studied.

24 April 2025 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Closed access
PDF file
ZSZhan Su
Zhan Su
YXYujie Xu
Yujie Xu
SLShanshan Liu
Shanshan Liu
TLTianlan Li
Tianlan Li
XFXianqi Feng
Xianqi Feng

1 April 2020
Verified
Journal Article
Closed access
QYQian Yang
Qian Yang
SNShu-Min Nie
Shu-Min Nie
TLTian-Lan Li
Tian-Lan Li
JHJun-Xia Huang
Jun-Xia Huang
SLShan-Shan Liu
Shan-Shan Liu
XFXianqi Feng
Xianqi Feng

1 January 2024 in Therapeutic Advances in Hematology
Verified
Journal Article
Open access
HXHan Xu
Han Xu
YXYujie Xu
Yujie Xu
MWMengying Wang
Mengying Wang
CMChunxia Mao
Chunxia Mao
JHJunxia Huang
Junxia Huang
XFXianqi Feng
Xianqi Feng
Background: Secondary myelofibrosis (SMF) is characterized by the excessive deposition of fibrous tissue on top of the primary disease, often causing clinical manifestations to be overshadowed by the primary disease. Unfortunately, current staging systems do not incorporate myelofibrosis, leading to potential treatment delays for SMF. Objectives: To evaluate the prognosis of patients with multiple myeloma (MM) complicated with myelofibrosis Design: The study included the clinical data and treatment results of 208 newly diagnosed multiple myeloma (NDMM) patients who were treated in the Affiliated Hospital of Qingdao University from January 2014 to August 2020, and performed a retrospective analysis. Methods: All patients underwent bone marrow biopsy, and MF severity was classified into grades 0–3 according to the 2016 WHO criteria. Treatment efficacy was evaluated based on the International Myeloma Working Group (IMWG) standard and SPSS was used for analysis. Results: The MM patients without SMF exhibited better treatment response ( p < 0.05). Importantly, increasing degrees of myelofibrosis were associated with a significant reduction in median progression-free survival (PFS; p < 0.05). MM-SMF patients exhibited significantly shorter median PFS and overall survival (OS; p < 0.05). In the MM-SMF group, neutrophil–lymphocyte ratio >2.39, monocyte–lymphocyte ratio ⩽0.18, and platelet–lymphocyte ratio ⩽61.6 were associated with significantly reduced median PFS and OS ( p < 0.05). Notably, the use of bortezomib-based regimens did not significantly impact prognosis in MM-SMF patients, while lenalidomide-based regimens significantly extended median OS but did not significantly affect median PFS. Conclusion: Myelofibrosis emerges as an important prognostic indicator for predicting the survival outcomes of NDMM patients. In the era of new therapeutics, there is a pressing need to explore novel treatment strategies in order to improve the prognosis of patients with multiple myeloma complicated by myelofibrosis.


18 March 2021 in Research Square
Verified
Preprint
Open access
PDF file
JHJunxia Huang
Junxia Huang
JHJuanjuan Hu
Juanjuan Hu
YGYan Gao
Yan Gao
FMFanjun Meng
Fanjun Meng
TLTianlan Li
Tianlan Li
XFXianqi Feng
Xianqi Feng
Background: Advanced lung cancer inflammation index (ALI) is known to predict the overall survival of patients having some solid tumors or B-cell lymphoma. The study investigates the predictive value of ALI in multiple myeloma (MM) patients and the correlation between ALI and prognosis.Methods: A database of 269 MM consecutive patients who underwent chemotherapy between December 2011 and June 2019 in the Affiliated Hospital of Qingdao University was reviewed. ALI cut-off value calculated before the initial chemotherapy and post 4 courses treatment were identified according to the receiver operating characteristic (ROC) curve, and its association with clinical characteristics, treatment response, overall survival (OS), and progression-free survival (PFS) were assessed.Results: Patients in the low ALI group (n=147) had higher risk of β2 microglobulin elevation, more advanced ISS (International Classification System stage), and TP53 gene mutation, with significantly lower median overall survival (OS; 36.29 vs. 57.92 months, P = 0.010) and progression-free survival (PFS; 30.94 vs. 35.67 months, P = 0.013). Independent risk factors influencing the OS of MM patients were ALI (P = 0.007), extramedullary infiltration (P = 0.001), TP53 (P = 0.020), Plt (P = 0.005), and bone destruction (P = 0.024). ALI (P = 0.005), extramedullary infiltration (P = 0.004), TP53 (P = <0.001), Plt (P = 0.017), and complex chromosome karyotype (P = 0.010) were independent risk factors influencing the PFS of MM patients.Conclusions: ALI is a potential independent risk factor predicting the prognosis of newly diagnosed MM patients.